



Annual Meeting of Stockholders

May 7th, 2008





Introduction

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2007, and subsequent SEC filings.

The US Healthcare & Clinical Laboratory Testing Market

2007 Projected US Healthcare Spend \$2.3 Trillion



- Total market size—\$50 billion
- Industry CAGR of 5%-7%
- Market Segments:
 - Routine—\$30-\$35 billion
 - Esoteric—\$4-\$5 billion
 - Anatomic pathology—\$6-\$10 billion

Source: CMS, Office of the Actuary, G-2, and Company Estimates

The Value of Lab Testing

In the past, lab testing was primarily used to diagnose disease

Now, lab testing now plays an increasingly large role in the full continuum of healthcare delivery

PREVENTION

DIAGNOSIS


TREATMENT

MONITORING




The Value of Lab Testing

Sources of Growth in Projected Federal Spending on Medicare and Medicaid (Percentage of GDP)



Source: Congressional Budget Office, November 2007


Lab Utilization and the Aging Population



Lab test utilization increases significantly with age and has increased for all age groups over time

The Cost Effectiveness of Lab Testing

Lab testing improves patient outcomes at dramatically reduced costs




LabCorp performs more than 10 million pap tests per year

For more examples on the value of lab testing, please visit www.labresultsforlife.org

The Cost Effectiveness of Lab Testing


Litholink Kidney Stone Disease Program

\$2,000+ Annual Cost Reductions Per Patient Per Year *



* Parks JH, Coe FL, *Kidney International*, vol. 50 (1996), pp. 1706-1712.

What is LabCorp



Strategic Focus Areas



Scientific Leadership

- Cancer diagnostics and monitoring
- Advanced cardiovascular disease testing
- Advancement through acquisitions and licensing



Managed Care

- Lab data enables better treatment and outcomes
- Partner to control high cost leakage
- Recognize value of lab services through appropriate pricing




Customer Focus

- Quality and service driven culture
- First-time problem resolution
- Continuous enhancements in customer connectivity

Revenue Growth Drivers

Industry Forces

- Focus on Outcomes and Cost Containment (Medical & Drug)
- Increased emphasis on drug efficacy, proper dosage and adverse effects
- Advances in science and genomics




EBITDA Margin Growth Drivers

1. Increased volumes through fixed-cost infrastructure
2. Larger number of esoteric tests offered, more esoteric tests ordered

3. Further operational efficiencies

- Increase automation in pre-analytic processes
- Logistics / route structure optimization
- Supply chain management




- Improved patient experience and data capture
- Long term Improvement in collections / bad debt

LabCorp's Investment and Performance Fundamentals

- **Industry-leading EBITDA margins**
- **Significant free cash flow**
- **Focus on providing value to shareholders**
 - Strategic acquisitions
 - Organic growth opportunities
 - Share repurchase
 - \$370.1 Million available as of 3/31/08
- **Flexibility for future growth opportunities**

Five-Year Revenue and EPS Trend


Revenue CAGR of 8.5% – Diluted EPS CAGR of 18.6%



1. Excluding the \$0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss.
2. Excluding the \$0.06 per diluted share impact in 2006 of restructuring and other special charges.
3. Excluding the \$0.25 per diluted share impact in 2007 of restructuring and other special charges.


Five-Year OCF and EBITDA Margin Trend

OCF CAGR of 6% – EBITDA Margin Growth of 210 bps



1. Includes approximately \$50 million of benefit from one-time tax credits recorded in 2003.
2. Excluding the impact in 2005 of restructuring and other special charges and a non-recurring investment loss.
3. Excluding the impact in 2006 and 2007 of restructuring and other special charges
4. As a result of adopting FASB 123(R) in 2006, the Company recorded incremental stock compensation expense of \$23.3 and \$26.7 in 2006 and 2007, respectively.

LabCorp 5-Year Stock Performance





 **LabCorp**
Laboratory Corporation of America